Logo

Luminex

DiaSorin 2022 Revenues Grow 10 Percent

For 2023, total revenues are expected to decline 14 percent year over year, and COVID-19 revenues are expected to be down 75 percent to €60 million.

DiaSorin Gets FDA 510(k) for Molecular COVID-19/Flu Assay

The real-time RT-PCR Simplexa COVID-19 & Flu A/B Direct assay is designed for use on the company's Liaison MDX instrument, with results in about one hour.

DiaSorin Selling Luminex Flow Cytometry Business to Cytek Biosciences for $46.5M

The cash deal for the DiaSorin subsidiary's flow cytometry and imaging business adds to Cytek's technological capabilities and global reach.

New Products Posted to GenomeWeb: Qiagen, Boston Heart Diagnostics, Bio-Techne, More

New products posted to GenomeWeb for the week of Aug. 15, 2022.

Luminex Obtains CE Marking for MDx Panel to Detect Flu A/B, RSV, COVID-19

Results are generated in a single workflow from a patient sample, which enables rapid detection for the differential diagnosis of a single pathogen.

Mar 17, 2022

DiaSorin Expects 2022 Revenue Growth From Base Business, Luminex as COVID-19 Testing Declines
Premium

Mar 16, 2022

DiaSorin 2021 Revenues Rise 41 Percent on SARS-CoV-2, Luminex Sales Growth

Mar 8, 2022

Luminex Gets CE Mark for Gastrointestinal Pathogen Panel

Feb 1, 2022

Genetic Analysis Receives CE Mark for Microbiome Test on Luminex Magpix Instrument

Nov 11, 2021

DiaSorin Q3 Revenues Rise 51 Percent on Luminex Acquisition, Recovery of Non-COVID Test Sales

Jul 30, 2021

DiaSorin Q2 Revenues Rise 20 Percent on SARS-CoV-2 Testing Demand

May 14, 2021

DiaSorin Q1 Revenues Rise 53 Percent on SARS-CoV-2 Testing Demand

Apr 13, 2021

With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio, Expand US Presence
Premium

Apr 12, 2021

DiaSorin to Acquire Luminex for $1.8B

Mar 4, 2021

Luminex Obtains FDA Emergency Use Authorization for Expanded Respiratory Panel With SARS-CoV-2

Feb 25, 2021

Luminex Shares Surge on Rumor of Acquisition by DiaSorin

Feb 19, 2021

Luminex Nabs $11.3M From BARDA to Develop Test for SARS-CoV-2, Flu, RSV

Feb 9, 2021

Luminex Moving Ahead With EUA Applications Despite Deprioritization of SARS-CoV-2 Test Submission
Premium

Feb 8, 2021

Luminex Q4 Revenues Rise 23 Percent; FDA Deprioritizes EUA Submission for COVID-19 Test

Jan 14, 2021

JP Morgan Healthcare Conference 2021, Day 3: Exact Sciences, Danaher, NanoString, Bio-Techne, More

Jan 12, 2021

Luminex Preliminary Q4 Revenues Increase 23 Percent on MDx Strength

Nov 5, 2020

Luminex Q3 Revenues Rise 35 Percent on Coronavirus Testing Demand

Oct 7, 2020

Luminex Preliminary Q3 Revenues Rise 35 Percent on Pandemic-Related Demand

Sep 8, 2020

As Flu Season Nears, Dx Companies Shift Attention to Multiplex Tests for SARS-CoV-2, Influenza
Premium

Aug 27, 2020

As Abbott Stock Rises on EUA for Antigen Test, Competitors' Shares Take a Hit

Breaking News
The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.